UCB stakes claim to gMG market as FDA clears Rystiggo

The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be used for two of the most common forms of the muscle-wasting autoimmune disease.